Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and Venetoclax + Chemotherapy in Pediatric/Young Adult Relapsed/Refractory AML or ALAL
NCT04898894Phase 1Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor and venetoclax in acute myeloid leukemia (AML) and acute leukemia of ambiguous lineage (ALAL), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Recommended Phase 2 Dose at 35 days, Number of patients treated at 35 days and 2 more. Started Nov 2021; status: active, not recruiting.
02
Drugs
selinexorvenetoclax
03
Conditions
acute myeloid leukemia (AML)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on NCT04898894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04898894.